OncoArendi Therapeutics Sp. z o.o plans to launch an IPO in March or April, Reuters reported.
The Warsaw, Poland-based biopharmaceutical company will issue between 500,000 and 2 million new shares.
OncoArendi, which specializes in drugs for cancer and respiratory diseases, will offer about 90% of the shares to institutional investors and about 10% to retail investors.
Trigon Dom Maklerski, an investment banking firm, is acting as intermediary in the offer.
